We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Former GSK Exec Faces Charges Over Off-Label Wellbutrin Promotion
Former GSK Exec Faces Charges Over Off-Label Wellbutrin Promotion
November 12, 2010
A former GlaxoSmithKline (GSK) vice president and associate general counsel is accused of withholding documents from the FDA that apparently show off-label promotion of its antidepressant Wellbutrin.